Legal Opinion
Shire Development, LLC v. Watson Pharmaceuticals, Inc.
Court of Appeals for the Federal Circuit
Decided February 10, 2017No. 2016-1785PublishedCited by 6 opinions
1Opinion of the Court
HUGHES, Circuit Judge.
Plaintiffs (collectively, Shire) sued Defendants (collectively, Watson) for infringing claims 1 and 3 of U.S. Patent No. 6,773,720 by filing Abbreviated New Drug Application No. 203817 with the Food and Drug Administration seeking to market a generic version of Shire’s mesalamine drug, LIALDA®. Because Watson’s ANDA Product does not satisfy the Mar-kush group requirements in claim 1(b), we reverse and remand with instructions to enter judgment of non-infringement.
I
A
The ’720 patent is directed to a controlled-release oral pharmaceutical composition of mesalamine (also…
2Cases cited14 opinions
- Wahpeton Canvas Co. v. Frontier, Inc.Court of Appeals for the Federal Circuit · 1989
- Conoco, Inc. v. Energy & Environmental International, L.C.Court of Appeals for the Federal Circuit · 2006
- Ak Steel Corporation v. Sollac and Ugine, Defendants-CrossCourt of Appeals for the Federal Circuit · 2003
- Ppg Industries v. Guardian Industries Corp.Court of Appeals for the Federal Circuit · 1998
- Georgia-Pacific Corporation, Plaintiff-Cross v. United States Gypsum Company and L&w Supply CorporationCourt of Appeals for the Federal Circuit · 1999
9 more not listed; retrieve them via the Exa API.
3Cited by6 opinions
- Velocity Patent LLC v. FCA US LLCDistrict Court, E.D. Illinois · 2018
- Amgen Inc. v. Amneal Pharmaceuticals LLCCourt of Appeals for the Federal Circuit · 2020
- EMED Technologies Corporation v. Repro-Med Systems, Inc. d/b/a RMS Medical ProductsDistrict Court, S.D. New York · 2019
- Ravgen, Inc. v. Natera, Inc.District Court, W.D. Texas · 2024
- TherapeuticsMD, Inc. and Mayne Pharma LLC v. Teva Pharmaceuticals USA, Inc.District Court, D. New Jersey · 2026
1 more not listed; retrieve them via the Exa API.